利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1038 条记录 (耗时 0.04 秒)

    Multimodal abuse resistant and extended release opioid formulations
    5.
    发明授权
    Multimodal abuse resistant and extended release opioid formulations 有权
    多模式滥用抗性和延长释放阿片类药物

    公开(公告)号：US09125833B2

    公开(公告)日：2015-09-08

    申请号：US12597702

    申请日：2008-04-26

    申请人： Najib Babul

    发明人： Najib Babul

    IPC分类号： A61K9/42 ,  A61K31/44 ,  A61K9/48 ,  A61K9/20 ,  A61K9/26

    CPC分类号： A61K9/4866 ,  A61K9/485 ,  A61K9/4858 ,  A61K31/44

    摘要： The present invention is in the field of oral, abuse resistant pharmaceutical compositions of opioid agonists, extended release pharmaceutical compositions of opioid agonists and extended release abuse resistant pharmaceutical compositions of opioid agonists and the use thereof. The present invention is also directed to extended release pharmaceutical compositions and the use thereof for preventing or minimizing the risk of abuse and/or toxicity from either intentional or unintentional tampering. The present invention is further directed at a method of preventing or minimizing the risk of abuse and/or toxicity from either intentional or unintentional tampering.

    摘要翻译： 本发明涉及阿片类激动剂的口服，滥用药物组合物，阿片样物质激动剂的延长释放药物组合物和阿片样物质激动剂的缓释滥用药物组合物及其用途。 本发明还涉及延长释放药物组合物及其用于预防或最小化由有意或无意篡改引起的滥用和/或毒性风险的用途。 本发明进一步涉及一种防止或最小化有意或无意篡改的滥用和/或毒性风险的方法。

    Pharmaceutical compositions comprising an active substance from the substituted benzhydrylpiperazine family
    6.
    发明授权
    Pharmaceutical compositions comprising an active substance from the substituted benzhydrylpiperazine family 有权
    药物组合物包含取代的二苯甲基哌嗪族的活性物质

    公开(公告)号：US08962022B2

    公开(公告)日：2015-02-24

    申请号：US12057177

    申请日：2008-03-27

    申请人： Gopi Venkatesh

    发明人： Gopi Venkatesh

    IPC分类号： A61K9/20 ,  A61K9/26 ,  A61K9/24 ,  A61K31/497 ,  C07D295/00 ,  A61K9/00 ,  A61K9/50

    CPC分类号： A61K9/0056 ,  A61K9/2077 ,  A61K9/5026 ,  A61K9/5047 ,  A61K9/5078

    摘要： The present invention is directed to compositions of taste-masked microparticles comprising a substituted benzhydrylpiperazine coated and a taste-masking layer comprising a water-insoluble polymer and a gastrosoluble polymer, and methods of making such taste-masked microparticles. The present invention is also directed to stable orally disintegrating compositions comprising taste-masked microparticles of a substituted benzhydrylpiperazine and rapidly dispersing granules, and methods of making such orally disintegrating compositions.

    摘要翻译： 本发明涉及包含取代的二苯甲基哌嗪涂层和包含水不溶性聚合物和胃溶性聚合物的掩味层的掩味微粒的组合物，以及制备这种掩味微粒的方法。 本发明还涉及包含取代的二苯甲基哌嗪和快速分散颗粒的掩味微粒的稳定的口腔崩解组合物，以及制备这种口腔崩解组合物的方法。

    Film-coated tablet or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound
    8.
    发明授权
    Film-coated tablet or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound 有权
    含有作为活性成分的吡啶嘧啶化合物或该化合物的药学上可接受的盐的薄膜包衣片剂或颗粒剂

    公开(公告)号：US08877238B2

    公开(公告)日：2014-11-04

    申请号：US13102109

    申请日：2011-05-06

    申请人： Lambert Tillmann Röhrich ,  Beat W. Müller

    发明人： Lambert Tillmann Röhrich ,  Beat W. Müller

    IPC分类号： A61K9/14 ,  A61K9/22 ,  A61K9/26 ,  A61K9/28 ,  A61K9/20

    CPC分类号： A61K9/2095 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059

    摘要： Film-coated tablet, consisting of a tablet core with a film coating, or granules containing as active ingredient a pyridylpyrimidine compound or a pharmaceutically acceptable salt of this compound, preferably imatinib or a pharmaceutically acceptable salt of imatinib, preferably imatinib monomethanesulfonate, wherein (i) the tablet cores and the granules have been produced by pressing of the starting materials and, prior to pressing of the starting materials, at least one of them has been dry-granulated, preferably compacted; (ii) the tablet cores and granule cores contain the active ingredient in a proportion of 25% by weight to 80% by weight, based on the total weight of the tablet cores or granule cores, together with (iii) at least one filler-binder, and optionally contain other additives; and (iv) the mean particle size distribution of at least 80% of the active ingredient is in the range from 0.01 mm to 1.0 mm.

    摘要翻译： 由具有薄膜包衣的片芯或包含作为活性成分的吡啶嘧啶化合物或该化合物的药学上可接受的盐的优选伊马替尼或伊马替尼的药学上可接受的盐，优选伊马替尼单甲磺酸盐的薄膜包衣片，其中（i ）通过压制原料制备片芯和颗粒，并且在压制起始材料之前，其中至少一种已经被干造粒，优选压实; （ii）基于片芯或颗粒芯的总重量，片芯和颗粒核含有25重量％至80重量％的活性成分，以及（iii）至少一种填料 - 粘合剂，并且任选地含有其它添加剂; 和（iv）活性成分的至少80％的平均粒度分布在0.01mm至1.0mm的范围内。

    Solid oral dosage form containing an enhancer
    10.
    发明授权
    Solid oral dosage form containing an enhancer 有权
    含有增强剂的固体口服剂型

    公开(公告)号：US08828431B2

    公开(公告)日：2014-09-09

    申请号：US13690082

    申请日：2012-11-30

    申请人： Merrion Research III Limited

    发明人： Kenneth Iain Cumming ,  Zebunnissa Ramtoola

    IPC分类号： A61K9/20 ,  A01N25/34 ,  A61K9/26 ,  A61K9/00 ,  A61K47/12 ,  A61K9/16 ,  A61K9/28

    CPC分类号： A61K9/0002 ,  A61K9/1617 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/2846 ,  A61K47/12

    摘要： The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.

    摘要翻译： 本发明涉及一种固体口服剂型，其包含与提高活性成分的生物利用度和/或吸收的增强剂组合的药物活性成分。 因此，固体口服剂型包括药物和增强剂，其中增强剂是中链脂肪酸酯，醚或盐或中链脂肪酸的衍生物，其优选在室温下为固体，并且其具有 碳链长度为6至20个碳原子。 优选地，固体口服剂型是控释剂型，例如延迟释放剂型。